Theralase Technologies Inc.
TLTFF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.98 | 0.51 | -0.81 | 0.80 |
| FCF Yield | -5.38% | -10.08% | -7.35% | -5.52% |
| EV / EBITDA | -15.70 | -9.66 | -14.15 | -17.25 |
| Quality | ||||
| ROIC | -181.61% | -200.42% | -146.70% | -88.95% |
| Gross Margin | 53.61% | 52.52% | 55.17% | 39.70% |
| Cash Conversion Ratio | 0.78 | 0.89 | 0.97 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.18% | 11.09% | 7.01% | -6.79% |
| Free Cash Flow Growth | 18.59% | 20.55% | -25.22% | 10.40% |
| Safety | ||||
| Net Debt / EBITDA | -0.01 | -0.08 | 0.21 | 0.89 |
| Interest Coverage | -177.68 | -151.10 | -246.20 | -850.16 |
| Efficiency | ||||
| Inventory Turnover | 0.88 | 0.77 | 1.05 | 0.83 |
| Cash Conversion Cycle | 332.61 | 115.16 | 175.54 | 94.41 |